Halozyme Therapeutics, INC 8-K filings

Halozyme Therapeutics reported a 27% year-over-year increase in fourth-quarter revenue and announced a new $750 million share repurchase program, while reiterating its 2024 financial guidance.

Halozyme Therapeutics estimates its 2023 revenue to be between $827 million and $832 million, with net income between $292 million and $297 million.